Magdy Elserafy

High prevalence of HCV (GT4)-related TSH abnormality among 13402 Egyptian patients treated with direct acting antiviral therapy

M. Said, W. Doss, K. Elsaeed, 2018, Hepatology International.

High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naïve and experienced chronic hepatitis C genotype 4: Real world results

W. Doss, M. Alboraie, H. Omar, 2019, Journal of medical virology.

Role of endoscopic ultrasound and cyst fluid tumor markers in diagnosis of pancreatic cystic lesions

S. Elkholy, H. Okasha, M. El-Ansary, 2022, World Journal of Gastrointestinal Endoscopy.

High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

I. Waked, W. Elakel, G. Esmat, 2019, Expert review of gastroenterology & hepatology.

Inter-method variability of hepatitis B surface antigen quantification in a cohort of Egyptian patients with chronic hepatitis B virus.

H. Gamal Eldeen, M. Abdo, N. Zayed, 2021, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.

M. Elsayed, M. Hassany, E. Safwat, 2021, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.

Efficacy and safety of ombitasvir/paritaprevir/ritonavir-based therapy in HCV patients with chronic kidney disease.

W. Elakel, W. Doss, Mai Mehrez, 2023, Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology.